Clinical Trials Logo

Clinical Trial Summary

This is a single arm, open-label, phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T, an autologous tri-functional anti- CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in Refractory/ Relapsed CD19 Positive Non-Hodgkin Lymphoma (NHL).


Clinical Trial Description

The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the CD19-TriCAR-T to simultaneously targeting the CD19 positive NHL cells,blocking the inhibitory PD-L1 signal and stimulating T/NK cell activation and expansion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03720496
Study type Interventional
Source Timmune Biotech Inc.
Contact Haifeng Lin
Phone +86 13322060949
Email 13322060949@163.com
Status Recruiting
Phase Phase 1
Start date November 1, 2018
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05050461 - Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma N/A
Recruiting NCT06160362 - The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) N/A
Recruiting NCT04435743 - Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Recruiting NCT02081937 - CART-19 Immunotherapy in Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT06321289 - Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Recruiting NCT05631912 - TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Completed NCT04094142 - Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Phase 2
Not yet recruiting NCT06156774 - SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
Recruiting NCT05143112 - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05909059 - CAR T-cell Therapy in Patients With Renal Dysfunction Phase 2
Recruiting NCT04661020 - CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT03497533 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 Phase 1/Phase 2
Recruiting NCT04532268 - A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Early Phase 1
Terminated NCT03488251 - PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT05741359 - The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04897477 - Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2